Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
NEW YORK, Oct. 25, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Intercept Pharmaceuticals, Inc. ("Intercept") (NASDAQ:ICPT) securities between May 31, 2016 and September 20, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sb/intercept-pharmaceuticals-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) the Company's lead product candidate, Ocaliva, entailed undisclosed safety risks, including death, to patients suffering from primary biliary cholangitis; and (ii) as a result of the foregoing, Intercept’s public statements were materially false and misleading at all relevant times. On September 12, 2017, Intercept issued a letter warning physicians against overdosing patients with Ocaliva, advising them that the drug has been tied to liver injuries and death among patients suffering from PBC. On September 21, 2017, the FDA issued a safety announcement warning doctors after reports of multiple deaths linked to the drug.
If you suffered a loss in Intercept you have until November 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sb/intercept-pharmaceuticals-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
